Caroline Maher

Title: Caroline Maher: Innovator in Cancer Treatment

Introduction

Caroline Maher is a prominent inventor based in Denver, Colorado, known for her significant contributions to cancer treatment through innovative methods. With a total of three patents to her name, she has made strides in predicting patient responses to antibody drugs, particularly in the context of immune checkpoint inhibitors.

Latest Patents

Her latest patents focus on a predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein. This method involves obtaining mass spectrometry data from a blood-based sample of the patient and analyzing integrated intensity values of predetermined mass-spectral features. A programmed computer implements a classifier that compares these values with a training set of class-labeled mass spectral data from melanoma patients. The classifier generates a class label indicating whether a patient is likely to benefit more or less from the antibody drug, thus aiding in personalized treatment plans.

Career Highlights

Caroline works at Biodesix, Inc., where she continues to develop innovative solutions for cancer diagnostics and treatment. Her work is pivotal in enhancing the understanding of how patients respond to specific therapies, ultimately improving patient outcomes.

Collaborations

Some of her notable coworkers include Krista Meyer and Julia Grigorieva, who contribute to the collaborative environment at Biodesix, Inc. Together, they work towards advancing cancer treatment methodologies.

Conclusion

Caroline Maher's innovative approaches in cancer treatment exemplify the impact of research and technology in medicine. Her patents not only reflect her expertise but also hold the potential to transform patient care in oncology.